CombinatoRx Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations

Monday, 06 July 2009 05:19

CAMBRIDGE, Mass.--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the advance online publication by CombinatoRx scientists of an extensive analysis of their discovery screening, scheduled to appear in the August issue of Nature Biotechnology. These new findings provide evidence that multi-target synergistic combinations may be more therapeutically specific than single agents.

By performing a comprehensive synergy analysis across pairs of assays covering six different disease areas and ~100,000 combinations, CombinatoRx scientists have empirically shown that synergistic combinations may yield greater therapeutic selectivity than single drugs. Therapeutic selectivity occurs when a treatment has more beneficial than toxic effect. Additional preclinical analysis by the authors on sample combinations shows that this selectivity results from coordinated context-specific multi-target activity.

“The demonstrated increase in therapeutic selectivity by synergistic combinations has important implications for drug discovery”, said Alexis Borisy, founder and scientific advisor to CombinatoRx. “It expands how we define and think about drug targets, and shows how controlling complex biology is all about coordinated activity on multiple nodes in a disease network”.

“This systematic exploration of combination therapy is made possible through the CombinatoRx combination high throughput screening (cHTS™) technology, the potential of which has been demonstrated through notable pharmaceutical partnerships, such as our recent oncology alliance with Novartis,” said Robert Forrester, Interim President and CEO of CombinatoRx. “The CombinatoRx business strategy will continue to leverage our unique drug discovery platform.”

About CombinatoRx:

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action, striking at the biological complexities of human disease. The CombinatoRx proprietary drug discovery technology provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx, please visit www.combinatorx.com.

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section

Add this page to your favorite Social Bookmarking websites